Insulet (PODD) Misses Q4 EPS by 22c, Guidance Comes in Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Insulet Reports Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 4:01 PM ESTBILLERICA, Mass., Feb. 25, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System (OmniPod System), today announced financial results for the three months and full year ended December 31, 2015.       Â
Fourth Quarter Highlights and Recent Developments:
Fourth Quarter revenue of $100.1 million exceeds the Company's guidance of $86 to $96 million and represents year-over-year growth of 38%. U.S. OmniPod revenue up 21% to $52.9 million. International OmniPod revenue up 16% to $15.4 million. Drug Delivery revenue of $14.7 million (prior year was $0.8 million).... More